HEPION PHARMACEUTICALS, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
HEPION PHARMACEUTICALS, INC. (HEPA) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $0 as of 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2024-04-16
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $0.00.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $957.00K.
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $957.00K.
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $957.00K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-04-16 |
| 2022-12-31 | $957.00K 10-K · filed 2024-04-16 |
| 2021-12-31 | $957.00K 10-K · filed 2023-04-10 |
| 2020-12-31 | $957.00K 10-K · filed 2022-04-08 |
| 2019-12-31 | $957.00K 10-K · filed 2022-04-08 |
| 2018-12-31 | $957.00K 10-K · filed 2020-05-14 |
| 2017-12-31 | $896.70K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |